Literature DB >> 10390148

Evaluation of seprase activity.

T Kelly1.   

Abstract

Seprase is a serine protease that is integral to the plasma membrane and is overexpressed by invasive tumor cells (Piñeiro-Sánchez et al., J Biol Chem 1997; 272: 7595-601; Monsky et al., Cancer Res 1994; 54: 5702-10). Seprase activity is most often assessed by zymography, which is not a quantitative assay. This study establishes a relatively simple and quantitative method for determining seprase activity. The degradation of a 3H-gelatin substrate is measured in the presence of 5 mM EDTA which inhibits matrix metalloproteinases but not seprase. The quantitative character of the assay was demonstrated using partially purified seprase from chicken embryos, a preparation that lacks detectable matrix metalloproteinase activity. In this assay, release of 3H-gelatin fragments is linear over time for 1.5 microg/assay seprase concentration as well as for preparations concentrated or diluted by five fold (7.5 microg/assay and 0.3 microg/assay respectively). Additional experiments were performed to validate the quantification of seprase activity using the radiographic assay by comparing the results to zymography. Exposure to 22 or 37 degrees C results in maximal seprase activity while exposure to 80 or 100 degrees C completely abolishes seprase activity in both zymography and the radiographic assay. Exposure to 60 degrees C abolished seprase activity as judged by zymography, but about 50% gelatinase activity was observed using the 3H-gelatin substrate. Immunopreciptiation with seprase-specific antibody specifically removed seprase and lowered the seprase activity remaining in the extracts as judged by both assays. Investigation of the seprase that was partially purified from human breast cancer tissue revealed that its specific activity (cpm gelatin fragments released/{mg protein x h}) is five times greater than that of seprase purified from chicken embryos. This assay will be useful for determining the seprase activity in extracts of tumor tissues and cells as well as for identifying inhibitors of seprase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390148     DOI: 10.1023/a:1026430206274

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  11 in total

1.  Radiolabeling of proteins and viruses in vitro by acetylation with radioactive acetic anhydride.

Authors:  R C Montelaro; R R Rueckert
Journal:  J Biol Chem       Date:  1975-02-25       Impact factor: 5.157

2.  Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins.

Authors:  T Kelly; S C Mueller; Y Yeh; W T Chen
Journal:  J Cell Physiol       Date:  1994-02       Impact factor: 6.384

3.  Phase separation of integral membrane proteins in Triton X-114 solution.

Authors:  C Bordier
Journal:  J Biol Chem       Date:  1981-02-25       Impact factor: 5.157

4.  Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates.

Authors:  C Heussen; E B Dowdle
Journal:  Anal Biochem       Date:  1980-02       Impact factor: 3.365

5.  Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.

Authors:  M L Piñeiro-Sánchez; L A Goldstein; J Dodt; L Howard; Y Yeh; H Tran; W S Argraves; W T Chen
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

6.  A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells.

Authors:  A Aoyama; W T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

7.  Molecular cloning of seprase: a serine integral membrane protease from human melanoma.

Authors:  L A Goldstein; G Ghersi; M L Piñeiro-Sánchez; M Salamone; Y Yeh; D Flessate; W T Chen
Journal:  Biochim Biophys Acta       Date:  1997-07-10

Review 8.  Proteases associated with invadopodia, and their role in degradation of extracellular matrix.

Authors:  W T Chen
Journal:  Enzyme Protein       Date:  1996

9.  Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.

Authors:  T Kelly; S Kechelava; T L Rozypal; K W West; S Korourian
Journal:  Mod Pathol       Date:  1998-09       Impact factor: 7.842

10.  Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family.

Authors:  W G Stetler-Stevenson; H C Krutzsch; L A Liotta
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

View more
  5 in total

1.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

2.  Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions.

Authors:  Yan Huang; Avis E Simms; Anna Mazur; Sophie Wang; Noel R León; Barry Jones; Nazneen Aziz; Thomas Kelly
Journal:  Clin Exp Metastasis       Date:  2011-05-22       Impact factor: 5.150

3.  Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.

Authors:  Johnna D Goodman; Tricia L Rozypal; Thomas Kelly
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma.

Authors:  Tomoya Kawase; Yumiko Yasui; Sohji Nishina; Yuichi Hara; Izumi Yanatori; Yasuyuki Tomiyama; Yoshihiro Nakashima; Koji Yoshida; Fumio Kishi; Masafumi Nakamura; Keisuke Hino
Journal:  BMC Gastroenterol       Date:  2015-09-02       Impact factor: 3.067

5.  Cleavage of Type I Collagen by Fibroblast Activation Protein-α Enhances Class A Scavenger Receptor Mediated Macrophage Adhesion.

Authors:  Anna Mazur; Emily Holthoff; Shanthi Vadali; Thomas Kelly; Steven R Post
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.